# Novartis and Samsung Biologics expand biologics manufacturing partnership

Samsung Biologics disclosed it is significantly expanding a 2022 pact with Novartis for biologics manufacturing. The expansion is valued at $309 million over five years.

- Type: Contract
- Announced: 2023-07-10
- Value: $309.0M
- Status: announced
- Products: biologics
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Samsung Biologics](https://endata.com/companies/15584.md) (supplier)
- [Novartis](https://endata.com/companies/32041.md) (customer)

## Sources

- [endpts.com](https://endpts.com/novartis-and-samsung-ink-five-year-309m-expansion-to-biologics-manufacturing-partnership/), 2023-07-10: "Samsung Biologics disclosed Monday that it’s significantly expanding a 2022 pact with Novartis to help with the Swiss company’s biologics manufacturing."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.